American Liver Foundation Applauds Biden Administration’s Proposed Rule Change on Anti-Obesity Medication Coverage under Medicare and Medicaid

Statement from Lorraine Stiehl, Chief Executive Officer, American Liver Foundation

“American Liver Foundation applauds the Biden Administration for its proposed rule change to expand Medicare and Medicaid coverage for FDA-approved anti-obesity medications. This critical step underscores a commitment to addressing the widespread impact of obesity, which is a leading risk factor for liver disease, including metabolic dysfunction-associated steatotic liver disease (MASLD).”

“MASLD affects an estimated 80-100 million Americans and results from an excessive buildup of fat in the liver. It is strongly linked to obesity, being present in 75% of individuals who are overweight and 90% of those with severe obesity. With more than 2 in 5 adults in the U.S. living with obesity—41.3% of women and 39.2% of men—this rule change has the potential to improve the health and well-being of millions.”

“By expanding access to critical medications that can help address obesity, this effort has the potential to reduce the prevalence of MASLD and the significant health complications associated with it. For liver patients, this means a chance to prevent the progression of liver disease, improve overall quality of life, and reduce healthcare burdens caused by untreated obesity and its complications.” 

“American Liver Foundation is encouraged by this proactive step toward addressing one of the most significant public health challenges of our time. We stand ready to support this initiative and ensure liver patients benefit from this critical effort. We thank the Biden Administration for prioritizing the health of millions and taking meaningful action to combat obesity and its devastating impact on liver health.”